GlaxoSmithKline News and Research

RSS

Prozac, Paxil, Wellbutrin, Zoloft, Celexa, Effexor, Luvox and Remeron should have "Black Box" warnings

A panel of experts has voted 15 to 8 in favour of the Federal Food and Drug Administration (FDA) adding black box warnings to certain medications used to treat depression in children and teenagers.

14 Sep 2004

Schering-Plough and Bayer form strategic alliance

Schering-Plough Corporation has announced that it has entered into a strategic agreement with Bayer designed to maximize the companies' pharmaceutical resources while maintaining each company's own strategic interests.

13 Sep 2004

Researchers have produced a marathon mouse that can run twice as far as normal mice

By enhancing the function of a single protein, Howard Hughes Medical Institute researchers have produced a “marathon mouse” with altered muscle composition and enough physical endurance to run twice as far as normal mice.

23 Aug 2004

Failing to disclose the results of clinical trials kills patients

Failing to disclose the results of clinical trials kills patients and wastes money, and government regulation is needed to put a stop to it, argues Sir Iain Chalmers in a letter to this week's BMJ.

20 Aug 2004

Researchers study whether people’s genetic makeup could make them more likely to develop osteoarthritis of the knee and hip

Researchers at The University of Nottingham are studying whether people’s genetic makeup could make them more likely to develop osteoarthritis of the knee and hip — the most common medical condition to affect the joints.

3 Aug 2004

FDA approval for mint flavor nicotine gum

Watson Pharmaceuticals announced today that it has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Application for nicotine polacrilex gum, mint flavor, in the 2 and 4 mg strengths.

3 Aug 2004

Drug to fight virus from the herpes family in transplant patients moves forward in trials

A drug once considered for cancer chemotherapy is advancing in clinical trials to test its effectiveness in fighting a virus from the herpes family that threatens transplant patients.

29 Jul 2004

GlaxoSmithKline to stand trial on AIDS drugs

The Competition Tribunal of South Africa agreed late last week to hear the complaint filed by individual South Africans and AIDS Healthcare Foundation, a nongovernmental organization that operates a free AIDS treatment clinic in Durban, that British drug maker GlaxoSmithKline illegally excessively priced AIDS drugs in violation of the South African Competition Act.

26 Jul 2004

Court ruling favors State over pharmaceutical manufacturers

Nevada Attorney General Brian Sandoval yesterday announced that Washoe County District Court Judge Steven R. Kosach has issued an important ruling in Nevada's Average Wholesale Price (AWP) litigation against numerous pharmaceutical manufacturers including Abbott Labs, Baxter, Bristol-Myers Squibb, Dey, GlaxoSmithKline, and Pharmacia.

21 Jul 2004

AIDS Healthcare Foundation targets GSK over voluntary licensing of its AIDS drug patents in South Africa

At the international AIDS conference in Bangkok, AIDS Healthcare Foundation hosted a peaceful protest against British multinational pharmaceutical giant GlaxoSmithKline over its voluntary licensing of its AIDS drug patents in South Africa.

13 Jul 2004

New guidelines for pulmonary arterial hypertension caution the use of calcium channel blockers

A new evidence-based guideline for pulmonary arterial hypertension (PAH) cautions the use of calcium channel blockers, a commonly used treatment for high blood pressure, in unstable patients due to the potentially fatal side effects associated with the medication.

13 Jul 2004

Study evaluates effectiveness of LEXIVA/ritonavir and Lopinavir/ritonavir in protease inhibitor

HIV treatment regimens containing the protease inhibitor (PI) LEXIVA® (fosamprenavir calcium) dosed with ritonavir (LEXIVA/r) or lopinavir (LPV) and ritonavir (LPV/r) were effective in suppressing HIV in patients who had failed prior PI-containing regimens, according to information presented at the International AIDS Conference (IAC).

12 Jul 2004

GSK and Boehringer Ingelheim to develop treatment for HIV infection specifically for the developing world

GlaxoSmithKline and Boehringer Ingelheim announced today that the companies have signed a letter of intent for an accelerated development programme for a co-package for Combivir® (lamivudine/zidovudine) and Viramune® (nevirapine) for chronic treatment of HIV infection in the developing world.

12 Jul 2004

Exelixis files new drug application for a proprietary novel anticancer compound

Exelixis, Inc. has submitted an investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA) for XL999, a proprietary novel anticancer compound.

29 Jun 2004

A viral respiratory infection common in children increases the risk of developing asthma

The study, published in The Journal of Infectious Diseases, is the first to show a link between respiratory syncytial virus, or RSV, infection and asthma in mice. A related study, also in mice, suggests that a medication neutralizing the virus could decrease children's chances of developing asthma.

28 Jun 2004

Drug companies spend about 37% of their overall R&D budgets on clinical affairs

Over the last decade, clinical services industry growth has exploded. Today, study sponsors dedicate significant portions of their budgets to CROs, SMOs and patient recruiters to access the expertise needed to speed trials to safe and successful fruition.

23 Jun 2004

New eye-tracking device

The newest research device at The William and Ida Friday Institute for Educational Innovation looks more like something out of a science fiction movie than a tool for discovering learning patterns.

21 Jun 2004

New York State accuses GlaxoSmithKline of fraudulent behaviour

This week's editorial calls on GlaxoSmithKline (GSK) to make all its research on paroxetine (Seroxat/Paxil) publicly available. This follows the filing of last week's law suit by the state of New York against GSK: the state accuses the company of fraud

11 Jun 2004

GlaxoSmithKline statement on spat with Spitzer

GlaxoSmithKline has acted responsibly in conducting clinical studies in pediatric patients and disseminating data from those studies. All pediatric studies have been made available to the FDA and regulatory agencies worldwide.

3 Jun 2004

Study shows herpes is common in suburban populations, with Denver up to 20 percent

According to a recent study of 36 primary care physician (PCP) offices in relatively affluent suburban areas of six U.S. cities, one in four people (25.5 percent) tested positive for the virus that causes genital herpes, despite the fact that only four percent of all those tested reported a history of the condition.

24 May 2004